These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28364988)

  • 21. Nationwide estimates of medication therapy management delivery under the Medicare prescription drug benefit.
    Pestka DL; Zillich AJ; Coe AB; Farris KB; Adeoye OA; Snyder ME; Farley JF
    J Am Pharm Assoc (2003); 2020; 60(3):456-461. PubMed ID: 31926872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and implementation of a telephone medication therapy management program for Medicare beneficiaries.
    Moczygemba LR; Barner JC; Gabrillo ER; Godley PJ
    Am J Health Syst Pharm; 2008 Sep; 65(17):1655-60. PubMed ID: 18714113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Online Provision of Part D Medication Therapy Management Program Information.
    Tong Z; Cooke CE; Brandt NJ
    J Manag Care Spec Pharm; 2019 Aug; 25(8):898-903. PubMed ID: 31347982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upcoming changes to Medicare Part D affect MTM services.
    Thompson CA
    Am J Health Syst Pharm; 2012 Jun; 69(11):910, 912. PubMed ID: 22610016
    [No Abstract]   [Full Text] [Related]  

  • 25. Understanding the landscape of MTM programs for Medicare. Part D: Results from a study for the Centers for Medicare & Medicaid services.
    Shoemaker SJ; Hassol A
    J Am Pharm Assoc (2003); 2011; 51(4):520-6. PubMed ID: 21752775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders.
    Donohue JM; Frank RG
    Psychiatr Serv; 2007 Oct; 58(10):1285-91. PubMed ID: 17914004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns and predictors of older adult Medicare Part D beneficiaries' receipt of medication therapy management.
    Coe AB; Adeoye-Olatunde OA; Pestka DL; Snyder ME; Zillich AJ; Farris KB; Farley JF
    Res Social Adm Pharm; 2020 Sep; 16(9):1208-1214. PubMed ID: 31859225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicare medication therapy Management: Beneficiary characteristics and utilization patterns in a national CMS Medicare fee-for-service sample (2013 to 2016).
    Oyarzún-González X; Abner EL; Freeman P; Kucharska-Newton A; Fardo DW; Moga DC
    J Am Pharm Assoc (2003); 2024; 64(5):102140. PubMed ID: 38825153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format.
    Brandt NJ; Cooke CE; Sharma K; Chou J; Carden MJ; Kumbera P; Pellegrin K
    J Manag Care Spec Pharm; 2019 Mar; 25(3):366-391. PubMed ID: 30816816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of an open enrollment service on costs for Medicare Part D beneficiaries.
    Leonard CE; Cohenour FV; DeLoach LA; Galdo JA
    J Am Pharm Assoc (2003); 2017; 57(3S):S225-S228. PubMed ID: 28412055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicare Part D-a roundtable discussion of current issues and trends.
    Balfour DC; Evans S; Januska J; Lee HY; Lewis SJ; Nolan SR; Noga M; Stemple C; Thapar K
    J Manag Care Pharm; 2009; 15(1 Suppl A):3-9. PubMed ID: 19125555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with medication-related problems in an ambulatory medicare population and the case for medication therapy management.
    Rogan EL; Ranson CA; Valle-Oseguera CS; Lee C; Gumberg A; Nagin BN; Cao W; Wang E; Trinh C; Chan K; Samra NK; Hou EW; Patel RA
    Res Social Adm Pharm; 2020 Jun; 16(6):783-786. PubMed ID: 31447267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survey of medication therapy management programs under Medicare part D.
    Touchette DR; Burns AL; Bough MA; Blackburn JC
    J Am Pharm Assoc (2003); 2006; 46(6):683-91. PubMed ID: 17176683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicare Part D: how do vulnerable beneficiaries fare?
    Summer L; Nemore P; Finberg J
    Issue Brief (Commonw Fund); 2008 Apr; 35():1-11. PubMed ID: 18536146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting Medicare Part D beneficiaries' decision to receive comprehensive medication reviews.
    Doucette WR; Zhang Y; Chrischilles EA; Pendergast JF; Newland BA; Farris KB; Frank J
    J Am Pharm Assoc (2003); 2013; 53(5):482-7. PubMed ID: 24030125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.
    Gray C; Cooke CE; Brandt N
    Am Health Drug Benefits; 2019 Sep; 12(5):243-251. PubMed ID: 32015791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Helping Medicare patients benefit from the new Medicare drug benefit: an overview with practice tips.
    Donohue J; Hanlon JT
    Am J Geriatr Cardiol; 2005; 14(6):291-7. PubMed ID: 16276125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.